Open AccessA Promising Single Oral Disintegrating Tablet for Co-Delivery of Pitavastatin Calcium and Lornoxicam Using Co-Processed Excipients: Formulation, Characterization and Pharmacokinetic Study
Author(s) -
Mahmoud H. Teaima,
KHALED M. ABDEL-HALEEM,
Rewan Osama,
Mohamed A. El-Nabarawi,
Osama S. Elnahas
Publication year - 2021
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s332729
Subject(s) - lornoxicam , pharmacokinetics , pharmacology , chemistry , pitavastatin , friability , in vivo , drug , chromatography , medicine , analgesic , atorvastatin , first pass effect , microbiology and biotechnology , biology
Statins are an important class of drugs that help to control hyperlipidemia, and one of these statins recently used is pitavastatin calcium (PITA). Nevertheless, the most reported adverse effect of statins is myopathy. Therefore, combining statins with non-steroidal anti-inflammatory drugs (NSAIDs) as Lornoxicam (LORNO) can help in the management of statin-induced myopathy.